Core Viewpoint - The company has achieved a significant legal victory regarding its original research product Budesonide Enteric-Coated Capsules (Nai Fukan®), with the Guangzhou Intellectual Property Court ruling in favor of the company's request for pre-litigation preservation of rights, ordering related generic drug companies to cease infringement activities and stop listing the product [1] Group 1 - The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's pre-litigation preservation application [1] - The court's ruling mandates that relevant generic drug companies immediately stop infringing activities and cease product listings [1] - The ruling is effective immediately upon issuance [1]

Core Viewpoint - The company, CloudTop New Medicine (01952.HK), has made significant progress in patent protection for its original product, Budesonide Enteric-Coated Capsules (Nai Fu Kang®), following a favorable ruling from the Guangzhou Intellectual Property Court [1] Group 1: Legal Developments - The Guangzhou Intellectual Property Court issued a civil ruling on February 26, 2026, fully supporting the company's pre-litigation preservation application [1] - The court ordered relevant generic drug companies to immediately cease infringement activities and stop listing their products [1] - The ruling is effective immediately upon issuance, reflecting the court's commitment to upholding intellectual property rights [1] Group 2: Company Commitment - The company expressed its welcome for the court's fair ruling and reiterated its commitment to legally protect intellectual property [1] - The company aims to promote innovative therapies to benefit more patients [1]

Core Viewpoint - The company, Genting New Year (01952.HK), has noted the approval of a generic version of its patented product Budesonide Enteric Capsules (耐赋康®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company’s original product,耐赋康®, is protected by patent ZL200980127272.5, which is currently valid [1] - The patent rights will expire on May 7, 2029, and the company has registered relevant patent information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must obtain legal permission from the company before manufacturing, using, or selling products that fall under the patent protection before its expiration [1] Group 2 - The company reserves the right to take legal action against any infringement of the patent rights or violations of commitments made by generic drug applicants [1] - Generic drug applicants must adhere to their commitments if they submit a "Category 3 Declaration," promising not to market the drug before the patent expires [1]

Core Viewpoint - The company has noted the approval of a generic version of its product Budesonide Enteric-Coated Capsules (耐赋康®) by the National Medical Products Administration of China, while emphasizing the protection of its original product under a valid patent until May 7, 2029 [1] Group 1 - The company holds a patent (ZL200980127272.5) for its original product in China, which is currently valid [1] - The patent information has been registered with the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products that fall under the patent protection without the company's legal permission before the patent expires [1] Group 2 - The company reserves the right to take legal action against any infringement of the patent or violations of commitments made by generic applicants [1] - Generic applicants must adhere to their commitments if they submit a "Category 3 Declaration," promising not to market the drug before the patent expiration [1]

Group 1 - The board of directors of the company noted the approval of a generic version of its patented product Budesonide Enteric-Coated Capsules (耐赋康®) by the National Medical Products Administration of China [1] - The original product is protected by patent ZL200980127272.5, which is valid until May 7, 2029, and the company has registered this information on the Chinese drug patent information registration platform [1] - According to Chinese patent law, any entity or individual must not manufacture, use, promise to sell, or import products within the patent protection scope without the company's legal permission before the patent expires, or it will constitute patent infringement [1] Group 2 - The company is committed to introducing breakthrough therapies to China to meet urgent medical needs, emphasizing the importance of a robust patent protection system and effective regulations for the sustainable accessibility of innovative drugs [2] - The environment for intellectual property protection in China's pharmaceutical industry has been continuously optimized, providing strong support for pharmaceutical innovation and healthy industry development [2] - The company will continue to collaborate with various parties to respect and uphold intellectual property rights, adhere to relevant laws and regulations, and foster a fair competitive environment to promote the ongoing development and accessibility of innovative drugs for the benefit of Chinese patients [2]